Intrinsic Heart Rate
PreclinicalSmall molecule
Intrinsic Heart Rate is one of 18 small molecule programs targeting Orthostatic Intolerance. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Tachycardia
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Rapiblyk
AAultman Health Foundation
Approved
Zebeta
TevaPreclinical
Isoproterenol Hydrochloride
SanofiPreclinical
Neo-Synephrine
EExela Pharma Sciences, LLC.
Preclinical
Sandostatin
Sun PharmaPreclinical
Tylenol
KKenvue Brands
Preclinical
Neurontin
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intrinsic Heart Rate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSatish R. Raj